단일 세포 시퀀싱 시장 : 제품 유형, 기술, 최종 사용자, 용도별 - 세계 시장 예측(2026-2032년)

The Single Cell Sequencing Market is projected to grow by USD 7.25 billion at a CAGR of 14.39% by 2032.

Single cell sequencing has moved from a specialist research method to a core platform for high-resolution biology, enabling researchers to profile DNA, RNA, chromatin accessibility, immune receptors, proteins, and spatial context at the level of individual cells. The technology is reshaping genomics, oncology, immunology, neuroscience, developmental biology, infectious disease research, and cell therapy development by revealing cellular heterogeneity that bulk sequencing can obscure.

Demand is being reinforced by large-scale public and private programs such as the Human Cell Atlas, NIH-supported single-cell and brain-mapping initiatives, and expanding translational research programs in precision medicine. Across laboratories, the value proposition is clear: single cell sequencing supports deeper disease characterization, better biomarker discovery, more informed patient stratification, and improved understanding of drug response and resistance mechanisms.

Transformative Shifts in the Single Cell Sequencing Landscape

The single cell sequencing landscape is being transformed by multiomics, spatial biology, automation, and more scalable sample preparation. Researchers increasingly seek integrated workflows that connect single-cell transcriptomics with epigenomics, proteomics, immune profiling, and tissue architecture, shifting adoption from standalone sequencing assays toward end-to-end discovery platforms.

Another major shift is the movement from proof-of-concept studies to cohort-scale and clinical-adjacent research. Pharmaceutical organizations, academic medical centers, and contract research organizations are using single cell analysis to map tumor microenvironments, characterize immune responses, support minimal residual disease research, and evaluate cell and gene therapy products. This transition is driving demand for reproducible protocols, quality control standards, high-throughput instruments, and bioinformatics pipelines that can support regulated research environments.

Cumulative Impact of Artificial Intelligence on Single Cell Sequencing

Artificial intelligence is compounding the impact of single cell sequencing by improving data interpretation, cell-type annotation, trajectory inference, batch correction, and multimodal integration. Because single cell datasets often contain millions of measurements across thousands to millions of cells, machine learning is essential for identifying rare cell populations, detecting disease-associated states, and extracting biologically meaningful patterns from noisy, high-dimensional data.

AI also supports broader adoption of single cell sequencing by reducing analysis bottlenecks. Foundation models for biology, graph-based learning, automated cell annotation tools, and cloud-native analytics are helping laboratories accelerate discovery while improving reproducibility. The strongest opportunities are emerging where AI links single cell sequencing with clinical metadata, imaging, proteomics, and spatial transcriptomics to create more actionable disease maps and target-discovery workflows.

Key Regional Insights Across Global Single Cell Sequencing Markets

North America remains a leading region for single cell sequencing adoption due to strong biomedical funding, concentration of genomics innovation, advanced academic medical centers, and deep pharmaceutical R&D activity. The United States anchors regional momentum through cancer research networks, immunology programs, neuroscience consortia, and biotechnology innovation, while Canada contributes through population genomics, stem cell research, and translational medicine programs.

Europe is characterized by coordinated research infrastructure, strong public funding, and an emphasis on data governance. European institutions are prominent contributors to the Human Cell Atlas and related atlasing efforts, while the European Union's regulatory environment encourages standardized data management, ethical genomic research, and cross-border collaboration. Asia-Pacific is one of the most active expansion regions as China, Japan, South Korea, Australia, India, and Singapore invest in precision medicine, sequencing capacity, regenerative medicine, immuno-oncology, and cell therapy research.

Latin America, the Middle East, and Africa are earlier in adoption but are gaining relevance through expanding genomics infrastructure, infectious disease research, oncology programs, and international collaborations. Brazil and Mexico support regional life science activity in Latin America, GCC countries are investing in precision health and national genomics strategies, and African research networks are increasingly important for population diversity, pathogen surveillance, antimicrobial resistance studies, and equitable genomic representation.

Key Group Insights for Single Cell Sequencing Adoption

Within ASEAN, Singapore stands out as a regional hub for biomedical research, biomanufacturing, and precision medicine, with spillover opportunities across Malaysia, Thailand, Indonesia, Vietnam, and the Philippines as sequencing services, hospital-based research, and academic collaborations expand. ASEAN demand is closely tied to infectious disease, cancer biology, immune profiling, and translational research capacity building.

The GCC is advancing single cell sequencing through national healthcare modernization programs, precision medicine investments, and genomics-focused initiatives in countries such as Saudi Arabia, the United Arab Emirates, and Qatar. The European Union benefits from cross-border research frameworks, data-sharing standards, biobanking networks, and major public funding mechanisms that support single-cell atlases, rare disease research, cancer studies, and clinical research networks.

BRICS countries represent a broad growth corridor, with China and India driving scale, Brazil supporting Latin American biomedical research, Russia maintaining strengths in basic science and computational biology, and South Africa contributing to infectious disease and population diversity studies. G7 countries retain strong positions in technology development, pharmaceutical R&D, academic medicine, and clinical translation, while NATO-aligned markets benefit from established research infrastructure, cybersecurity standards, trusted data practices, and procurement systems that support advanced life science technologies.

Key Country Insights in Single Cell Sequencing

The United States leads in commercial innovation, academic adoption, and biopharma use of single cell sequencing, supported by strong NIH funding, cancer centers, and advanced genomics infrastructure. Canada is strengthening capabilities through stem cell science, cancer genomics, population health, and national research networks, while Mexico is gradually expanding sequencing applications in academic medicine, infectious disease, and public health research. Brazil is the key Latin American contributor due to its research universities, oncology centers, biobanks, and infectious disease expertise.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are major contributors to single cell research. The United Kingdom has a strong genomics ecosystem and leading participation in cell atlas programs; Germany combines engineering, life science tools, immunology, and translational research; France supports translational medicine, rare disease research, and national sequencing initiatives; Italy and Spain contribute through oncology, immunology, neuroscience, and academic hospital networks. Russia maintains scientific capacity in molecular biology and computational research, although international collaboration dynamics can affect market access and technology transfer.

In Asia-Pacific, China has rapidly scaled sequencing infrastructure and single-cell technology adoption, particularly in oncology, immunology, developmental biology, and immune cell profiling. India is expanding from genomics services and academic research into precision medicine, infectious disease studies, and biopharma applications. Japan is strong in regenerative medicine, stem cell biology, neuroscience, and clinical research quality. Australia contributes through cancer, immunology, genomics-enabled population health, and translational research, while South Korea combines advanced biotechnology, diagnostics, digital health, and cell therapy development to support growing single cell sequencing demand.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated single cell sequencing workflows that combine robust sample preparation, scalable library construction, high-quality sequencing, and validated bioinformatics. Partnerships with academic medical centers, pharmaceutical organizations, and contract research organizations can accelerate adoption by aligning technology capabilities with disease-specific use cases in oncology, immunology, neuroscience, infectious disease, regenerative medicine, and cell therapy.

Commercial strategies should emphasize reproducibility, total cost of ownership, data interoperability, and regulatory readiness. Vendors and service providers that offer standardized protocols, cloud-based analytics, AI-enabled interpretation, secure data governance, and clear quality metrics will be better positioned as single cell sequencing moves from exploratory research toward translational and clinical-adjacent applications.

Research Methodology for Single Cell Sequencing Insights

This executive summary is developed using a structured secondary-research methodology that evaluates publicly available evidence from peer-reviewed literature, government research programs, regulatory agencies, technology platform documentation, clinical research registries, patent activity, scientific conference proceedings, and recognized consortia. The assessment prioritizes verified signals such as research funding direction, publication activity, platform adoption, clinical research use cases, regional genomics infrastructure, and documented technology advancements.

The analysis applies cross-validation across market drivers, technology trends, regional capabilities, and end-user demand patterns. Insights are synthesized to support executive decision-making for technology suppliers, sequencing service providers, pharmaceutical organizations, research institutes, investors, and policy stakeholders active in the single cell sequencing ecosystem, while avoiding unsupported market sizing, market share, and forecasting claims.

Conclusion: Strategic Outlook for Single Cell Sequencing

Single cell sequencing is becoming a foundational technology for precision biology because it reveals the cellular diversity that drives disease progression, therapeutic response, immune function, and biological development. Its convergence with spatial biology, multiomics, automation, and AI is expanding adoption beyond discovery research into translational workflows with higher strategic value.

Organizations that invest in scalable platforms, strong data science capabilities, interoperable workflows, quality-controlled protocols, and region-specific partnerships will be best positioned to advance adoption. As global research ecosystems continue to prioritize precision medicine, cellular atlases, and genomics-enabled therapeutic discovery, single cell sequencing will remain central to the next generation of biology-driven innovation.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Single Cell Sequencing Market, by Product Type

• 7.1. Instruments
  • 7.1.1. Cell Sorters
  • 7.1.2. Microfluidic Devices
  • 7.1.3. Sequencers
• 7.2. Reagents And Kits
  • 7.2.1. Amplification Kits
  • 7.2.2. Labeling Kits
  • 7.2.3. Lysis Kits

8. Single Cell Sequencing Market, by Technology

• 8.1. Droplet Based
• 8.2. Microwell Based
• 8.3. Plate Based

9. Single Cell Sequencing Market, by End User

• 9.1. Academic Research
  • 9.1.1. Research Institutes
  • 9.1.2. Universities
• 9.2. Clinical Diagnostics
  • 9.2.1. Diagnostic Labs
  • 9.2.2. Hospitals
• 9.3. Clinical Research Organization
  • 9.3.1. Clinical Services
  • 9.3.2. Preclinical Services
• 9.4. Pharma & Biotech
  • 9.4.1. Biomarker Development
  • 9.4.2. Drug Discovery

10. Single Cell Sequencing Market, by Application

• 10.1. Cancer Research
  • 10.1.1. Circulating Tumor Cells
  • 10.1.2. Tumor Heterogeneity
• 10.2. Developmental Biology
• 10.3. Immunology
  • 10.3.1. Immune Repertoire Analysis
  • 10.3.2. T Cell Profiling
• 10.4. Neurology
  • 10.4.1. Neurodegenerative Disease
  • 10.4.2. Neuronal Profiling

11. Single Cell Sequencing Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Single Cell Sequencing Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Single Cell Sequencing Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. 10x Genomics, Inc.
• 15.2. Agilent Technologies, Inc.
• 15.3. Arima Genomics LLC
• 15.4. Becton, Dickinson and Company
• 15.5. BGI Group
• 15.6. Bio-Rad Laboratories, Inc.
• 15.7. CD Genomics
• 15.8. Cell Signaling Technology, Inc.
• 15.9. F. Hoffmann-La Roche Ltd
• 15.10. HiFiBiO Therapeutics, Inc.
• 15.11. Illumina, Inc.
• 15.12. iRepertoire, Inc.
• 15.13. Merck KGaA
• 15.14. Miltenyi Biotec GmbH
• 15.15. Oxford Nanopore Technologies plc.
• 15.16. Pacific Biosciences of California, Inc.
• 15.17. Parse Biosciences Inc.
• 15.18. QIAGEN GmbH
• 15.19. Revvity, Inc.
• 15.20. Standard BioTools Inc.
• 15.21. Takara Bio Inc.
• 15.22. Thermo Fisher Scientific, Inc.